Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Pediatric patients treated with CCPD who displayed biochemical and bone biopsy proven secondary hyperparathyroidism were randomly assigned to one of 2 vitamin D analogues (calcitriol or doxercalciferol) and one of two phosphate binders (sevelamer or calcium carbonate) in a two by two factorial designed prospective trial. Serum biochemical measurements were obtained at baseline and monthly throughout the 8 months of the trial. Bone biopsy was obtaine at baseline and repeated at study completion.
Age
2–21
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Stable end-stage kidney disease treated with continuous cycling peritoneal dialysis,
Biochemical evidence of secondary hyperparathyroidism (PTH\>400 pg/ml) with bone biopsy evidence of high turnover bone disease
You may not be if
History of parathyroidectomy
Growth hormone
Prednisone, or other immunosuppressant medication within the past year.
Recent history of medication non-compliance.
Clareo Health | Regulation of Bone Formation in Renal Osteodystrophy
